Morningstar

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Provided by Dow Jones Sep 24, 2026, 11:14:00 AM

By Colin Kellaher

Eli Lilly has won U.S. Food and Drug Administration approval for Onswik, a once-weekly basal insulin injection treatment for adults with type 2 diabetes.

Eli Lilly on Thursday said Onswik is designed to deliver steady basal insulin levels over seven days, eliminating the need for more than 300 injections a year compared to once-daily basal insulin.

The Indianapolis drugmaker said the Onswik KwikPen will be available in the U.S. in the coming months.

Onswik was previously approved for adults with type 2 diabetes in Europe, Mexico and Japan.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 24, 2026 07:14 ET (11:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

These Overvalued Stocks Have Plenty of Room to Fall

Why investors should be wary of a refiner and financial-services stock trading well above our fair value estimates.

David Sekera, CFA, Sarah Hansen, and Jess Bebel Nov 5, 2026

3 of the Best Dividend Stocks to Own

These dividend stocks with economic moats offer durable payouts.

Susan Dziubinski Nov 2, 2026

3 Stocks to Sell and 3 Stocks to Buy for November

Plus, whether Microsoft, Alphabet, or Amphenol look attractive after earnings.

David Sekera, CFA and Sarah Hansen Nov 2, 2026

4 Big Impacts from the US Midterm Elections for Investors

What analysts are saying the blue wave means for the AI trade, the debt ceiling, and Democrats’ legislative priorities.

Sarah Hansen Nov 4, 2026

US Midterms: How Markets Are Reacting to Democrats’ Congressional Gains

Stocks, bonds, and gold are moving as the Republican Party loses the Senate and House.

Karen Gilchrist and Vicky McKeever Nov 4, 2026

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.